J&J Not Sweating Remicade Biosimilar Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.